Adenosine and lymphocyte regulation

Purinergic Signalling

Volumn 3, Issue 1-2, 2007, Pages 109-116

  Gessi, Stefania ^a,b   Varani, Katia ^a,b   Merighi, Stefania ^a,b   Fogli, Eleonora ^a,b   Sacchetto, Valeria ^a,b   Benini, Annalisa ^a,b   Leung, Edward ^c   Mac Lennan, Stephen ^c   Borea, Pier Andrea ^a,b  

^a UNIVERSITY OF FERRARA   (Italy)

^b Ctro Naz Eccellenza per lo Sviluppo Meto Innov per lo Stud Trattamento Pato Infiammatorie   (Italy)

^c King Pharmaceuticals   (United States)

Author keywords

Adenosine receptors; Immunotherapy of cancer; Inflammation; T cells

Indexed keywords

EID: 33947702519     PISSN: 15739538     EISSN: 15739546     Source Type: Journal    
DOI: 10.1007/s11302-006-9042-y     Document Type: Article

References (53)

1. Fredholm BB, Ijzerman AP, Jacobson KA, Klotz KN, Linden J (2001) International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 53:527-552
2. Hershfield MS (2005) New insights into adenosine-receptor-mediated immunosuppression and the role of adenosine in causing the immunodeficiency associated with adenosine deaminase deficiency. Eur J Immunol 35:25-30
3. Buckley RH (2004) Molecular defects in human severe combined immunodeficiency and approaches to immune reconstitution. Annu Rev Immunol 22:625-655
4. Hershfield MS (2004) Combined immune deficiencies due to purine enzyme defects. In: Sthiem ER, Ochs HD, Winkelstein JA (eds) Immunologic disorders in infants and children, 5th edn. Saunders, Philadelphia, pp 480-504
5. Apasov SG, Blackburn MR, Kellems RE, Smith PT, Sitkovsky MV (2001) Adenosine deaminase deficiency increases thymic apoptosis and causes defective T cell receptor signalling. J Clin Invest 108:131-141
6. Wolberg G, Zimmerman TP, Hiemstra K, Winston M, Chu LC (1975) Adenosine inhibition of lymphocyte-mediated cytolysis: Possible role of cyclic adenosine monophosphate. Science 87:957-959
7. Sitkovsky M, Ohta A (2005) The danger sensors that stop the immune response: The A2 adenosine receptors? Trends Immunol 26:299-304
8. Decking UKM (1997) Hypoxia-induced inhibition of adenosine kinase potentiates cardiac adenosine release. Circ Res 81:154-164
9. Ledoux S (2003) Hypoxia enhances ecto-55′-nucleotidase activity and cell surface expression in endothelial cells. Circ Res 92:848-855
10. 2A adenosine receptor in vivo. J Immunol 173:21-24
11. Vivekanandhan S, Soundararajan CC, Tripathi M, Maheshwari MC (2005) Adenosine deaminase and 5′-nucleotidase activities in peripheral blood T cells of multiple sclerosis patients. Neurochem Res 30:453-456
12. Newby AC (1984) Adenosine and the concept of retaliatory metabolites. Trends Biochem Sci 9:42-44
13. Hasko G, Cronstein BN (2004) Adenosine: An endogenous regulator of innate immunity. Trends Immunol 25:33-39
14. Gessi S, Varani K, Merighi S, Ongini E, Borea PA (1999) A 2A adenosine receptors in human peripheral blood cells. Br J Pharmacol 129:2-11
15. 2A extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion. Blood 90(4):1600-1610
16. 2A purinergic receptor-mediated signaling in murine T cells. J Biol Chem 272:25881-25889
17. 2A receptor monoclonal antibodies. Mol Pharmacol 55:614-624
18. 2A adenosine receptor induction inhibits IFN-gamma production in murine CD4+ T cells. J Immunol 174:1073-1080
19. 2 receptors to inhibit IL-2-induced tyrosine phosphorylation of STAT5 in T lymphocytes: Role of cyclic adenosine 3′,5′-monophosphate and phosphatases. J Immunol 173(2):932-944
20. Minguet S, Huber M, Rosenkranz L, Schamel WWA, Reth M, Brummer T (2005) Adenosine and cAMP are potent inhibitors of the NF-kB pathway downstream of immunoreceptors. Eur J Immunol 35:31-41
21. Aldrich MB, Chen W, Blackburn MR, Martinez-Valdez H, Datta SK, Kellems RE (2003) Impaired germinal center maturation in adenosine deaminase deficiency. J Immunol 171:5562-5570
22. Cronstein BN (1994) Adenosine, an endogenous anti-inflammatory agent. J Appl Physiol 76(1):5-13
23. Hasko G, Szabo C, Nemeth ZH, Kvetan V, Pastores SM, Vizi ES (1996) Adenosine receptor agonists differentially regulate IL-10, TNF-alpha, and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice. J Immunol 157:4634-4640
24. Ohta A, Sitkovsky M (2001) Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 414:916-920
25. 2A adenosine receptor as a physiological immunosuppressor and to engineer inflammation in vivo. Biochem Pharmacol 65:493-501
26. 2A-receptor-gene-deficient mice. Biochem J 354:123-130
27. 3 adenosine receptors in lymphoid organs. Biochem Pharmacol 65(12):2081-2090
28. Chan ES, Cronstein BN (2002) Molecular action of methotrexate in inflammatory disease. Arthritis Res 4:266-273
29. Johnston A, Gudjonsson JE, Sigmundsdottir H, Ludviksson BR, Valdimarsson H (2005) The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clin Immunol 114(2):154-163
30. Gadangi P, Longaker M, Naime D et al (1996) The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites. J Immunol 156:1937-1941
31. Hwang KK, Hall CS, Spielman WS et al (2001) FK506 promotes adenosine release from endothelial cells via inhibition of adenosine kinase. Eur J Pharmacol 425:85-93
32. Blay J, White TD, Hoskin DW (1997) The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine. Cancer Res 57:2602-2605
33. Merighi S, Mirandola P, Varani K, Gessi S, Leung E, Baraldi PG, Tabrizi MA, Borea PA (2003) A glance at adenosine receptors: Novel target for antitumor therapy. Pharmacol Ther 100:31-48
34. Hoskin DW, Reynolds T, Blay J (1994) Colon adenocarcinoma cells inhibit anti-CD3-activated killer cell induction. Cancer Immunol Immunother 38(3):201-207
35. Hoskin DW, Reynolds T, Blay J (1994) Adenosine as a possible inhibitor of killer T-cell activation in the microenvironment of solid tumours. Int J Cancer 59(6):854-855
36. Hoskin DW, Reynolds T, Blay J (1994) 2-Chloroadenosine inhibits the MHC-unrestricted cytolytic activity of anti-CD3-activated killer cells: evidence for the involvement of a non- A1/A2 cell-surface adenosine receptor. Cell Immunol 159(1):85-93
37. 3 receptor. Cancer Res 54:3521-3526
38. 3 receptor to prevent the induction of murine anti-CD3-activated killer T cells. Int J Cancer 99:386-395
39. MacKenzie WM, Hoskin DW, Blay J (2002) Adenosine suppresses α4β 7 integrin-mediated adhesion of T lymphocytes to colon adenocarcinoma cells. Exp Cell Res 276:90-100
40. Walsh GM, Symon FA, Lazarovits AI, Wardlaw AJ (1996) Integrin α4β7 mediates human eosinophils interaction with MadCAM1, VCAM1 and fibronectin. Immunology 89:112-119
41. Michetti M, Kelly CP, Kraehenbuhul JP, Bouzourene H, Michetti P (2000) Gastric mucosal alpha(4)beta(7)-integrin-positive CD4 T lymphocytes and immune protection against helicobacter infection in mice. Gastroenterology 119:109-118
42. Elewaut D, De Keyser F, Van Den Bosch F, Lazarovits AI, De Vos M, Cuvelier C, Verbruggen G, Mielants H, Veys EM (1998) Enrichment of T cells carrying β7 integrins in inflamed synovial tissue from patients with early spondyloarthropathy, compared to rheumatoid arthritis. J Rheumatol 25:1932-1937
43. Butler JJ, Mader JS, Watson CL, Zhang H, Blay J, Hoskin DW (2003) Adenosine inhibits activation-induced T cell expression of CD2 and CD28 co-stimulatory molecules: Role of interleukin-2 and cyclic AMP signaling pathways. J Cell Biochem 89:975-991
44. Dong RP, Kameoka J, Hegen M, Tanaka T, Xu Y, Schlossman SF, Morimoto C (1996) Characterization of adenosine deaminase binding to human CD26 on T cells and its biologic role in immune response. J Immunol 156:1349-1355
45. Gorrell MD, Gysbers V, Mccaughan GW (2001) CD26: A multifunctional integral membrane and secreted protein of activated lymphocytes. Scand J Immunol 54:249-264
46. Dasmahapatra KS, Hill HZ, Dasmahapatra A, Suarez S (1986) Evaluation of adenosine deaminase activity in patients with head and neck cancer. J Surg Res 40:368-373
47. 3 adenosine receptors in Jurkat T cells. Br J Pharmacol 134:116-126
48. 3 adenosine receptors in human lymphocytes: Up-regulation in T cell activation. Mol Pharmacol 65:711-719
49. 2B adenosine receptors in human lymphocytes: their role in T cell activation. J Cell Sci 112:491-502
50. 3 H]-MRE 2029-F20. Mol Pharmacol 67:2137-2147
51. 3 adenosine receptor agonist potentiates natural killer cell activity. Int J Oncol 23(4):1245-1249
52. 3 adenosine receptor as a new target for cancer therapy and chemoprotection. Exp Cell Res 269:230-236
53. Raskovalova T, Huang X, Sitkovsky M, Zacharia LC, Jackson EK, Gorelik E (2005) Gs protein-coupled adenosine receptor signaling and lytic function of activated NK cells. J Immunol 175:4383-4391